Global health: The United States disrupts the supply of HIV and malaria drugs

The United States is preparing to fundamentally transform its system for distributing essential drugs against HIV and malaria, a decision that is raising serious concerns about the risk of shortages in the most vulnerable countries.

According to several sources, Washington plans to end the global health supply chain program as early as May 30. This key mechanism has enabled the delivery of life-saving treatments to dozens of low-income countries. The program, managed by the company Chemonics, has distributed more than $5 billion worth of medical supplies to approximately 90 countries, primarily in sub-Saharan Africa and Asia.

This change is part of a broader overhaul of international aid led by the president's administration. Donald TrumpThis plan notably includes reducing budgets, dismantling certain structures such as USAID, and prioritizing direct bilateral agreements with recipient states.

However, no clear replacement plan has been presented at this stage. State Department officials and other sources warn against a rushed transition, which could severely disrupt the supply of essential medicines and equipment, such as antiretroviral treatments or insecticide-treated bed nets.

This reorganization comes after a major disruption in 2025, when the freezing of US foreign aid blocked millions of dollars worth of supplies in ports and warehouses. Although some deliveries have resumed thanks to waivers, uncertainty remains regarding the continuity of services.

Experts fear these changes will directly affect millions of patients dependent on these programs, particularly in Africa. Ongoing discussions between the United States and some African countries to establish new agreements are already facing obstacles.

In the context of the global fight against diseases such as HIV/AIDS and malaria, this reorientation of American policy could have major consequences for public health, particularly in the most exposed regions.